ライフサイエンスコーパス: QOL

1 QOL did not differ from that of the general population,

2 QOL of patients with food allergy improves in some but d

3 QOL scores improved overall at 1 year (p < 0.001), with

4 QOL was assessed using the 4 subscales of the Physical C

5 QOL was improved through 12 months.

6 QOL was measured using the self-administered 36-item Sho

7 ng TAVR (death, 17.6%; very poor QOL, 11.6%; QOL decline, 2.0%) and 50.8% experienced a poor outcome

8 me at 1 year (death, 30.2%; poor QOL, 19.6%; QOL, decline 1.0%).

9 advanced fibrosis are most likely to achieve QOL benefits from weight loss.

10 BEV+IRI did not alter QOL compared with TMZ.

11 2; 95% confidence interval, -0.8 to 0.4) and QOL scale (mean difference at 24 months, -0.2; 95% confi

12 Functional (ALSFRS) and QOL measures were inversely related to disease stage.

13 Angina and QOL questionnaires were collected at baseline and months

14 Conclusions and Relevance: Burnout and QOL vary across all surgical specialties.

15 ancer Quality of Life Questionnaire C30, and QOL on the basis of the EuroQoL-5 Dimension scale.

16 the association between palliative care and QOL was attenuated but remained statistically significan

17 L), the association between chemotherapy and QOL amid progressive metastatic disease has not been wel

18 revascularization), total medical costs, and QOL.

19 e Seattle Angina Questionnaire frequency and QOL scales.

20 kelihood of success in terms of function and QOL.

21 raphics, medical history, health habits, and QOL.

22 erapy-oriented exercise on wound healing and QOL.

23 is trial confirms that PTC benefits mood and QOL cancer-specific and gynecologic concerns for a multi

24 produce differences in overall mortality and QOL.

25 ion (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure

26 Overall functional outcomes and QOL scores were acceptable.

27 ciated with equivalent clinical outcomes and QOL, and lower costs, compared with usual care over 1-ye

28 Pain perception and QOL were evaluated by using specific questionnaires.

29 r ejection fraction, and clinical status and QOL showed favorable trends.

30 s associated with impaired health status and QOL, the degree of impairment increased in a stepwise fa

31 significantly higher, and nasal symptoms and QOL disturbance of the patients seen in otorhinolaryngol

32 o required noninvasive testing, symptoms and QOL improved significantly.

33 aumatic stress disorder (PTSD) symptoms, and QOL 6 months post-transplant.

34 splant, we assessed mood, PTSD symptoms, and QOL with the Hospital Anxiety and Depression Scale and P

35 opsy, lifestyle assessment, blood tests, and QOL tools, including the Chronic Liver Disease Questionn

36 as associated with worse 6-month utility and QOL.

37 ported toxic effects between treatment arms, QOL analysis demonstrated a clinically meaningful declin

38 nd 3 months after HCT and caregiver-assessed QOL and mood at baseline and 2 weeks after HCT.

39 This study assessed QOL in GenTAC participants with MFS and identify associa

40 UAS may be a useful tool for assessing QOL in pediatric patients with chronic urticaria.

41 nd comorbid asthma completed the Mini Asthma QOL Questionnaire (miniAQLQ) and Asthma Control Test (AC

42 CRS-specific factors associated with asthma QOL or control or ESS outcomes.

43 Baseline QOL scores were lowest in those with late disease (P < 0

44 Baseline QOL was an independent prognostic factor for survival.

45 Patient demographics and baseline QOL scores were comparable between the 74-Gy and 60-Gy a

46 Of the 313 patients who completed baseline QOL assessments, 219 patients (70%) completed the 3-mont

47 uation, of whom 313 (88%) completed baseline QOL assessments.

48 Better QOL was independently associated with socioeconomic fact

49 tients experienced pain reduction and better QOL at day 10 after radiotherapy with further improvemen

50 ment goal was "to cure my cancer" had better QOL (B = 4.33; P = .03) and less anxiety (B = -1.39; P =

51 In bivariate analysis, predictors of better QOL included college education, marital status, higher h

52 ome patients with low FAQLQ-PF score (better QOL) at baseline deteriorated.

53 of positive reframing was related to better QOL (B = 2.61; P < .001) and less depression (B = -0.78;

54 Active coping was associated with better QOL (B = 3.50; P < .001) and less depression (B = -1.01;

55 Higher aMED is associated with better QOL and decreased pain, disability, and depressive sympt

56 anean diet (aMED) was associated with better QOL and decreased pain, stiffness, disability, and depre

57 Some patients with better QOL at baseline might deteriorate during OIT.

58 To determine the association between QOL and visual function as measured by 24-2 and 10-2 VFs

59 ssion, and determine the correlation between QOL and depression.

60 ific symptoms (CSI), and quality of life (CD-QOL).

61 NYHA functional classification, QOL, and clinical composite score were assessed at 6, 12

62 We compared QOL by HIV-NRD status, adjusting for potential confoundi

63 QOL) scores by Japanese rhino-conjunctivitis QOL questionnaire (JRQLQ No1), symptoms of nose and eye

64 QOL) scores by Japanese rhino-conjunctivitis QOL questionnaire (JRQLQ No1).

65 QOL) scores by Japanese rhino-conjunctivitis QOL questionnaire (JRQLQ No1).

66 eptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), a

67 ionships among prognostic awareness, coping, QOL, and mood in patients with newly diagnosed, incurabl

68 ct, P = .09; mood, P = .33) or before death (QOL, P = .73; symptom impact, P = .30; mood, P = .82).

69 cluding length of follow-up, cause of death, QOL, and primary end point, and their impact on trial in

70 to have higher symptom burden and decreased QOL.

71 lts was correlated moderately with decreased QOL.

72 Each QOL score improved in the overall study population (p <

73 aptive coping strategies in order to enhance QOL and mood.

74 statistically significant after enrollment (QOL, P = .34; symptom impact, P = .09; mood, P = .33) or

75 The primary outcome was the 6-month Euro QOL-5 Dimension (EQ-5D) index score (a measure of health

76 ty Cardiomyopathy Questionnaire and European QOL 5D Visual Analog Scale via multiple logistic regress

77 stionnaire, 3395 patients completed European QOL 5D Visual Analog Scale, and 1431 patients in United

78 athy Questionnaire was 54.8, and on European QOL 5D Visual Analog Scale, it was 60.3; 27% of patients

79 , did not provide an incremental benefit for QOL over 2 years of follow-up.

80 -1.1; SE, .4; d = -.44; P = .01) but not for QOL (mean difference, -4.9; SE, 2.6; d = -.3; P = .07),

81 orrelates well with assessments of function, QOL and health service costs.

82 h the newly developed SDQ and with a generic QOL tool (36-Item Short Form Health Survey).

83 an baseline-to-week-15 change in QLQ-C30 GHS/QOL score was 6.9 (95% CI 3.3 to 10.6) for pembrolizumab

84 ents who had a PD demonstrated better global QOL, physical- and role-functioning scores at 5-years wh

85 ols, PD survivors demonstrated higher global QOL (78.7 vs 69.7, CR small, P < 0.001), physical (86.7

86 Predefined secondary end points were global QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotiona

87 In contrast, GO-QOL appearance scores changed significantly by 6 weeks a

88 xplained 79% of the variance in change in GO-QOL appearance, with change in subjective evaluation of

89 utcomes significantly predicted change in GO-QOL visual function.

90 e Graves' Ophthalmopathy Quality of Life (GO-QOL) scale was completed at each time point, and this wa

91 The GO-QOL visual function scores did not change significantly

92 mean physical (PCS) and mental (MCS) health QOL composite scores and reporting long-term (>/=2 years

93 Higher QOL scores represent greater severity of symptoms.

94 tion patients vs control patients had higher QOL scores (mean, 112.00 vs 106.66; mean difference, 5.3

95 avoidant coping were associated with higher QOL and lower depressive symptoms at 24 weeks.

96 ted coping, which was associated with higher QOL and reduced depressive symptoms.

97 ysfunction, nor does it significantly impact QOL.

98 ic agents, were more likely to have impaired QOL and depression.

99 Patients with impaired QOL at baseline improve significantly despite the treatm

100 Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.

101 h palliative chemotherapy is used to improve QOL for patients with end-stage cancer, its use did not

102 better clinical outcomes, including improved QOL and heart failure status, compared with RV pacing.

103 urable cancers, early integrated PC improved QOL and other salient outcomes, with differential effect

104 ic for 3 months was associated with improved QOL at a single time point (24 weeks after therapy) comp

105 are lacking on whether weight loss improves QOL.

106 ng symptoms and SMS of JCP, and in improving QOL.

107 symptoms and TNSMS of JCP, and in improving QOL.

108 ng symptoms and SMS of JCP, and in improving QOL.

109 Secondary end points included change in QOL from baseline to week 24, change in depression per t

110 Changes in QOL from baseline to 90 days were assessed using the Sea

111 Comparing changes in QOL from baseline to day 42, responders had significantl

112 onstrated a clinically meaningful decline in QOL in the 74-Gy arm at 3 months, confirming the primary

113 h, poor quality of life (QOL), or decline in QOL, as assessed using the Kansas City Cardiomyopathy Qu

114 plant care resulted in a smaller decrease in QOL 2 weeks after transplantation.

115 vention group reported a smaller decrease in QOL from baseline to week 2 (mean baseline score, 110.26

116 18 to -0.86; P = .013), but no difference in QOL or anxiety.

117 There were no differences in QOL (mean difference, -2; SE, 2.3; d = -.13; P = .39) or

118 group reported no significant differences in QOL or anxiety but had a smaller increase in depression

119 omic variables, there were no differences in QOL or functional scores in the benign versus malignant

120 No differences were found in QOL measures.

121 There was a trend toward improvement in QOL for ivabradine versus placebo (p = 0.053).

122 usual care) reported greater improvement in QOL from baseline to week 24 (1.59 v -3.40; P = .010) bu

123 adiotherapy one can expect an improvement in QOL is unknown.

124 duces durable pain relief and improvement in QOL parameters.

125 There was a trend toward improvement in QOL parameters.

126 That was driven primarily by improvement in QOL scores in patients with high score (worse QOL) at ba

127 -13 had significantly greater improvement in QOL than those with increasing cytokine levels.

128 n BMI leads to a 10% adjusted improvement in QOL.

129 ts with lung cancer reported improvements in QOL and depression at 12 and 24 weeks, whereas usual car

130 n both study groups reported improvements in QOL and mood by week 12.

131 er radiotherapy with further improvements in QOL at day 42 in responders.

132 D can experience significant improvements in QOL that appear specific to weight loss and not biochemi

133 In the invasive cohort, the improvements in QOL were similar in the FFRCT and usual care patients.

134 .1 vs CF-WBI, 118.8; P = .46) and individual QOL items such as somewhat or more lack of energy (HF-WB

135 To investigate QOL at days 10 and 42 after radiotherapy with a bone met

136 To compare quality of life (QOL) after radical prostatectomy, external beam radiothe

137 studies that found improved quality of life (QOL) after radiotherapy of bone metastases have small sa

138 the Mediterranean diet and quality of life (QOL) among people living in North America.

139 s surgery (ESS) upon asthma quality of life (QOL) and asthma control using validated outcome metrics.

140 cessary to optimize patient quality of life (QOL) and daily functioning and minimize the risk of acut

141 n as it relates to impaired quality of life (QOL) and depression, identify predictors of poor QOL and

142 Our aim was to assess quality of life (QOL) and functionality in a large cohort of patients >/=

143 gnostic awareness and worse quality of life (QOL) and mood among patients with advanced cancer.

144 iative care (EIPC) improves quality of life (QOL) and mood for patients with advanced cancer.

145 ant care improves patients' quality of life (QOL) and symptom burden during hematopoietic stem-cell t

146 ef of symptoms and improved quality of life (QOL) despite a relatively high radiographically identifi

147 scular events [MACCE]), and quality of life (QOL) during the 5-year follow-up.

148 l studies suggested reduced quality of life (QOL) for people with Marfan syndrome (MFS) compared with

149 ary end point was change in quality of life (QOL) from baseline to week 12, per scoring by the Functi

150 damage with vision-related quality of life (QOL) has not been well studied.

151 ducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI pati

152 The time course of quality of life (QOL) in six selected domains of the European Organisatio

153 Quality of life (QOL) is impaired in patients with food allergy and impro

154 swallowing dysfunction and quality of life (QOL) of adult patients with surgically corrected EA/TEF.

155 mine the effect on cost and quality of life (QOL) of using FFRCT instead of usual care to evaluate st

156 burden of burnout and poor quality of life (QOL) on surgeons relies on a thorough understanding of Q

157 visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-conjunctivitis QOL questio

158 efficacy was evaluated with quality of life (QOL) scores by Japanese rhino-conjunctivitis QOL questio

159 visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-conjunctivitis QOL questio

160 nd satiety assessments, and quality of life (QOL) surveys, reported up to 3 months.

161 ed about their symptoms and quality of life (QOL) using the Japanese Rhinoconjunctivitis Quality of L

162 cally meaningful decline in quality of life (QOL) via the Functional Assessment of Cancer Therapy (FA

163 pe natriuretic peptide, and quality of life (QOL) were assessed.

164 Symptom burden and quality of life (QOL) were major secondary outcomes.

165 ist, estimated survival and quality of life (QOL) with and without transplant, comorbidities, and lif

166 e to support improvement in quality of life (QOL) with CPM.

167 ening in menopause-specific quality of life (QOL) with treatment discontinuation at 1 year.

168 ent-centered communication, quality of life (QOL), and aggressive treatments in advanced cancer, yet

169 g clinical composite score, quality of life (QOL), and change in New York Heart Association (NYHA) fu

170 Outcomes were quality of life (QOL), depression, and burden (objective, stress, and dem

171 was defined as death, poor quality of life (QOL), or decline in QOL, as assessed using the Kansas Ci

172 cancer and (b) evaluate the quality of life (QOL), pain perception, and efficacy in terms of time to

173 ion of palliative care with quality of life (QOL), symptom burden, survival, and other outcomes for p

174 early versus delayed PC on quality of life (QOL), symptom impact, mood, 1-year survival, and resourc

175 red chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid

176 or exercise on healing and quality of life (QOL), which is impaired in patients with VLUs.

177 diovascular risk," "overall quality of life (QOL)," "mortality," "technical complications of the spec

178 hological symptoms and poor quality of life (QOL).

179 rary DAPT and its impact on quality of life (QOL).

180 d associated with decreased quality of life (QOL).

181 ajor determinant of reduced quality of life (QOL).

182 Index (DLQI) which assesses Quality of Life (QOL).

183 is important to assess the quality of life (QOL).

184 of everyday functioning and quality of life (QOL).

185 nize their own symptoms and quality of life (QOL).

186 HIV-NRD on vision-specific quality of life (QOL).

187 or impact on health-related quality of life (QOL).

188 complications and decreased quality of life (QOL).

189 ptic neuritis episodes, and quality of life (QOL; based on the 54-item Multiple Sclerosis Quality of

190 included function (ALSFRS), quality of life (QOL; Short Form-36) and health service costs.

191 cervical cancer experience quality-of-life (QOL) disruptions that persist years after treatment.

192 uate trends in clinical and quality-of-life (QOL) measures in a cohort of patients with Lyme disease

193 e surgical, functional, and quality-of-life (QOL) outcomes of redo surgery for failed IPAA, especiall

194 ear clinical, economic, and quality-of-life (QOL) outcomes of using FFRCT instead of usual care.

195 duration of follow-up; and quality-of-life (QOL) outcomes were considered in terms of the results an

196 global health status (GHS)/quality-of-life (QOL) score and time to deterioration of the composite of

197 ively collected a battery of quality-of-life(QOL) instruments at baseline and at 6, 12, and 24 months

198 However, longitudinal QOL data are lacking on whether weight loss improves QOL

199 nth EQ-5D index score (p < 0.0001) and lower QOL (p < 0.001).

200 associated with long-term symptoms or lower QOL scores were other comorbidities unrelated to Lyme di

201 At first visit, overall mean QOL scores were below the US population mean for both PC

202 ts, 219 patients (70%) completed the 3-month QOL assessments, and 137 of the living patients (57%) co

203 The mean follow-up time for the 36-month QOL assessment was 43.5 months.

204 71] vs 2.23 [1.72]; P = .05) at the 36-month QOL assessment.

205 erall preoperative and 2-, 12-, and 36-month QOL scores were 28.50, 10.18, 9.74, and 10.58, respectiv

206 and identify items to propose new nystagmus QOL scales.

207 Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), d

208 We studied the association of QOL with self-reported demographics, health behaviors, p

209 We prospectively collected a battery of QOL instruments in 5985 patients at baseline and 6, 12,

210 sical fitness is an important determinant of QOL, and because cardiac function can influence exercise

211 dom-effects meta-analysis, with estimates of QOL translated to units of the Functional Assessment of

212 as to determine the prevalence and impact of QOL of rhinitis in swimming compared to nonswimming athl

213 less optimally to DBS by other indicators of QOL.

214 ncontinence, and the patients' perception of QOL.

215 mployment remained significant predictors of QOL.

216 and provide a comprehensive understanding of QOL and burnout among all surgeons, to delineate variati

217 rgeons relies on a thorough understanding of QOL and burnout among the various surgical specialties.

218 however, patients reported minimal effect on QOL or day-to-day activities.

219 coping accounted for intervention effects on QOL and depressive symptoms.

220 ignificantly mediated the effects of EIPC on QOL (indirect effect, 1.27; 95% CI, 0.33 to 2.86) and de

221 l telephone counseling (PTC) intervention on QOL domains and associations with biomarkers.

222 tigated the effect of these interventions on QOL and healing, and few involved the supervision of a p

223 here was no incremental benefit in angina or QOL measures by adding ranolazine in this angiographical

224 as reported in the no-CPM group in the other QOL domains.

225 reporting of long-term symptoms and overall QOL of Lyme disease patients and should be considered in

226 Longitudinal change in overall QOL and anxiety did not reach statistical significance.

227 icant heterogeneity in CTT, PAC-SYM, and PAC-QOL exists among studies.

228 essment of Constipation-Quality of Life (PAC-QOL) in adults diagnosed with functional constipation pe

229 ce, with older age associated with lower PAC-QOL scores.

230 were associated with improvements in patient QOL and symptom burden.

231 inically significant improvements in patient QOL at the 1- to 3-month follow-up (standardized mean di

232 We examined changes in patient QOL during OIT for food allergy.

233 mes and Measures: Primary: change in patient QOL from baseline to week 2; secondary: patient-assessed

234 mized 1:1 to oral ranolazine versus placebo; QOL analyses included 2389 randomized subjects.

235 a poor outcome at 1 year (death, 30.2%; poor QOL, 19.6%; QOL, decline 1.0%).

236 for burnout and more likely to report a poor QOL than attending surgeons.

237 neate variation in rates of burnout and poor QOL, and to elucidate factors that are commonly implicat

238 and depression, identify predictors of poor QOL and depression, and determine the correlation betwee

239 nths following TAVR (death, 17.6%; very poor QOL, 11.6%; QOL decline, 2.0%) and 50.8% experienced a p

240 and 5.31 [95% CI, 3.58 to 7.04]), and poorer QOL (4.70 [95% CI, 2.82 to 6.58] and 5.22 [95% CI, 3.61

241 t, decreased career satisfaction, and poorer QOL.

242 Posttransplant QOL was valued more highly than pretransplant QOL.

243 OL was valued more highly than pretransplant QOL.

244 The prespecified primary QOL measures were the Duke Activity Status Index and the

245 The primary QOL hypothesis predicted a clinically meaningful decline

246 4-Gy arm at 3 months, confirming the primary QOL hypothesis.

247 Following qualifying index PCI, the primary QOL outcome (Seattle Angina Questionnaire [SAQ] angina f

248 tionship, shared understanding of prognosis, QOL, and aggressive treatments and hospice use in the la

249 te the association of CPM with four BREAST-Q QOL domains.

250 elates with increased disability and reduced QOL.

251 he "eye" domain showed significantly reduced QOL in elite and nonelite swimmers compared to nonswimmi

252 scores indicate worse heart failure-related QOL; co-primary outcome).

253 lizumab improves or maintains health-related QOL compared with that for chemotherapy, and might repre

254 more deconditioning and lower health-related QOL in children after LT emphasize the importance of exe

255 Health-related QOL showed lower overall, emotional, psychosocial, and s

256 h MFS in the GenTAC registry, health-related QOL was below the population norm.

257 Health-related QOL was evaluated using child- and adolescent-reported P

258 hypothesis that patients with vision-related QOL disproportionate to their 24-2 VF status may exhibit

259 tagmus scales and an existing vision-related QOL tool, the Visual Function Questionnaire-25 (VFQ-25)

260 We assessed the vision-related QOL with the 25-item National Eye Institute Visual Funct

261 impact of ocular GVHD on the vision-related QOL, and thus the importance of comprehensive diagnosis

262 ence measurable impairment of vision-related QOL.

263 erstanding, patient-physician relationships, QOL, and aggressive treatments in the last 30 days of li

264 mmon Toxicity Criteria, and patient-reported QOL using the Functional Assessment of Cancer Therapy fo

265 Self-reported QOL was completed using the European Organisation for Re

266 interviewed about their financial reserves, QOL, and symptom burden at 4 months of diagnosis and, fo

267 -Bronchiectasis Respiratory Symptoms scores (QOL-B-RSS) at 4 weeks.

268 None of the secondary QOL measures showed a consistent strategy-related differ

269 ted gastroesophageal reflux disease-specific QOL tool to patients before and at 2, 12, and 36 months

270 the gastroesophageal reflux disease-specific QOL tool, and recurrence, defined as a PEH of greater th

271 usion Negative changes in menopause-specific QOL influence a woman's decision to stop chemoprevention

272 n or, especially, overall menopause-specific QOL, was associated with early treatment discontinuation

273 radiotherapy with a bone metastases-specific QOL tool.

274 have developed a 29-item, nystagmus-specific QOL questionnaire (NYS-29) based on eudaimonic aspects o

275 unctioning as relating to nystagmus-specific QOL.

276 l association with decreased vision-specific QOL among people with AIDS and good BCVA.

277 Although a few vitiligo specific QOL instruments exist, there is no specific vitiligo bur

278 nt-reported outcomes and, more specifically, QOL differed according to receipt of CPM.

279 tatus and treatment goal, coping strategies, QOL, and mood.

280 In the noninvasive stratum, QOL scores improved more in FFRCT patients than in usual

281 y about patient backgrounds, nasal symptoms, QOL disturbance, and treatment agents, for childhood all

282 Long-term QOL outcomes after PD for benign or malignant disease ar

283 ological mesh results in excellent long-term QOL.

284 The QOL data were collected prospectively via FACT Trial Out

285 It is necessary to develop the QOL questionnaire sheets for children with allergic rhin

286 significant correlations between each of the QOL scores and depression.

287 the adversely impact of pediatric JCP on the QOL of the parents is not understood.

288 III NSCLC randomized, 360 (85%) consented to QOL evaluation, of whom 313 (88%) completed baseline QOL

289 and included more than 1 question related to QOL were included.

290 unt for the effect of mortality on follow-up QOL measurement were consistent with the primary finding

291 Binocular visual function (VF and VA) and VR QOL.

292 p between vision-related quality of life (VR QOL; Visual Activities Questionnaire [VAQ] and the 25-it

293 Outcomes of interest were QOL [assessed with the 12-Item Short-Form Health Outcome

294 Outcomes were QOL, symptom impact, mood, 1-year survival, and resource

295 Primary end points were QOL scores and burnout rates that compared sex, age, lev

296 Outlier association with QOL was then assessed using a linear regression model, w

297 valuated usefulness of UAS by comparing with QOL score.

298 ted a terminally ill health status had worse QOL (unstandardized coefficient [B] = -6.88; P < .001),

299 OL scores in patients with high score (worse QOL) at baseline.

300 ion Prognostic awareness is related to worse QOL and mood in patients with newly diagnosed, incurable